Results 251 to 260 of about 131,634 (310)

Vaccines at the Heart of Hepatitis Elimination: Insights From the ESCMID Study Group for Viral Hepatitis (ESGVH)

Liver International, Volume 46, Issue 4, April 2026.
ABSTRACT The global elimination of viral hepatitis by 2030 remains an ambitious goal that hinges not only on diagnostics and therapeutics but fundamentally on the strategic use and continued innovation of vaccines. The ESCMID Study Group for Viral Hepatitis (ESGVH) convened to examine the role of vaccination as the cornerstone of hepatitis prevention ...
Oana Săndulescu, Gülşen Özkaya Şahin, Susanne Gjeruldsen Dudman, Zeinab Nabil Ahmed Said, Mario U. Mondelli, on behalf of ESCMID Study Group for Viral Hepatitis (ESGVH)   +5 more
wiley   +1 more source

Glycosomal Phosphoenolpyruvate Carboxykinase CRISPR/Cas9‐Deletion and Its Role in Trypanosoma cruzi Metacyclogenesis and Infectivity in Mammalian Host

The FASEB Journal, Volume 40, Issue 6, 31 March 2026.
Effects of PEPCK deficiency in Trypanosoma cruzi bioenergetics and life stages. ABSTRACT Trypanosoma cruzi, the causative agent of Chagas disease, possesses glycosomes—unique organelles that house key metabolic enzymes, several of which are promising therapeutic targets.
Carolina S. D. Vieira, Wei Wang, Fernando Sanchez‐Valdez, Jihyun Lim, Brooke E. White, Camilla G. S. Souza, Rick L. Tarleton, Marcia C. Paes, Natalia P. A. Nogueira   +8 more
wiley   +1 more source

Development of a Self‐Adjuvanting Influenza Peptide–Glycolipid Conjugate Inducing CD8+ T‐Cell Immunity

ChemBioChem, Volume 27, Issue 5, 13 March 2026.
The glycolipid‐peptide antigen complexes for self‐adjuvanting conjugates were successfully synthesized, and, with the HLA‐transgenic mice, the antigen‐specific CD8+ T cell expansion was exhibited. The results provide useful insights for the design and synthesis of vaccine conjugates using glycolipid antigen as an adjuvant.
Shunya Kikuchi, Hideki Ogura, Takanori Matsumaru, Satoshi Ishido, Yukari Fujimoto   +4 more
wiley   +1 more source

Quinic Acid and Synthetic Derivatives in Medicinal Chemistry

ChemMedChem, Volume 21, Issue 5, 13 March 2026.
Quinic acid and its derivatives are gaining recognition as versatile scaffolds in drug discovery. This review explores their emerging roles in inflammation, infection, cancer, and metabolic disorders, highlighting recent advances that position them beyond chlorogenic acids as promising platforms for therapeutic innovation. Quinic acid (QA) is a natural
Iago C. Vogel, Manuel J. Verganista, Nuno R. Candeias   +2 more
wiley   +1 more source

Catalytic Amyloids: Turning Fibrils Into Biocatalysts

Chemistry – A European Journal, Volume 32, Issue 10, 9 March 2026.
Amyloids, traditionally associated with diseases, have emerged as versatile catalytic scaffolds. From natural amyloid sequences to bioinspired and de novo designs, we highlight strategies to construct catalytic active sites and anchor enzymes onto fibrils, creating versatile nanomaterials with tunable activities. ABSTRACT Amyloids have been regarded as
Alessandra Esposito, Linda Leone, Flavia Nastri, Angela Lombardi   +3 more
wiley   +1 more source

[Inactivated polio vaccine].

Atencion primaria, 2005
openaire   +1 more source

By dawn or dusk—how circadian timing rewrites bacterial infection outcomes

FEBS Letters, Volume 600, Issue 6, Page 864-893, March 2026.
The circadian clock shapes immune function, yet its influence on infection outcomes is only beginning to be understood. This review highlights how circadian timing alters host responses to the bacterial pathogens Salmonella enterica, Listeria monocytogenes, and Streptococcus pneumoniae revealing that the effectiveness of immune defense depends not only
Devons Mo, Catherine S. Palmer, Jacqueline M. Kimmey   +2 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

An inactivated vaccine against ringworm

Comparative Immunology, Microbiology and Infectious Diseases, 1992
A new vaccine against ringworm, containing the inactivated Trichophyton verrucosum strain, was assessed on guinea pigs and calves under experimental conditions and on three herds of cattle under natural conditions. The vaccine elicited a distinct immune response of the cellular type.
K, Wawrzkiewicz, J, Wawrzkiewicz
openaire   +2 more sources

Inactivated virosome hepatitis A vaccine

The Lancet, 1994
Immunopotentiating reconstituted influenza virosomes (IRIV) are efficient carrier systems for small virion particles such as hepatitis A virus (HAV). We evaluated immunogenicity and tolerability of an IRIV-HAV vaccine and the effectiveness of a booster by immunising 104 healthy HAV seronegative volunteers. A single dose was highly immunogenic, since 98%
L, Loutan, P, Bovier, B, Althaus, R, Glück   +3 more
openaire   +2 more sources